Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.

Int J Mol Sci · 2022 · PMC8877618 · PMID 35216317

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Notably, serum cholesterol levels showed a trend of decreasing in response to losartan ( p = 0.07) and mirabegron ( p = 0.08) compared to the DOXO-only group ( Table 2 ).

also in 53,322 other papers

a decreasing trendp = 0.13not close (p > 0.1)

Lung weight showed a decreasing trend in the DOXO-only group compared to the control group ( p = 0.13).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.